A prospective, multicenter, open‐label, randomised, controlled clinical trial in Belgium (NCT04330638) compared the safety and effectiveness of individually or simultaneously blocking IL‐6 and IL‐1 versus standard of care, on blood oxygenation and systemic cytokine release syndrome, in patients with COVID‐19 and acute hypoxic respiratory failure. The gene discussed is IL6; the disease is COVID-19.